Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novasys Medical

This article was originally published in The Gray Sheet

Executive Summary

Non-surgical treatment for female stress urinary incontinence gains expanded R&D funding via $13 mil. private placement of preferred stock. Delphi Ventures, Onset Ventures, Alloy Ventures, Affinity Capital Advisors and Rothschild Bioscience Managers participated in the financing. A pilot study of 41 women with SUI in Chile and Mexico has been completed, and clinical results are being analyzed, Sunnyvale, California-based Novasys says. The radiofrequency catheter-based, bladder outlet remodeling device works by increasing bladder outlet resistance
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT015553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel